- In June 2024, Ipsen announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for treating primary biliary cholangitis (PBC). It is approved for use alongside ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy for those unable to tolerate UDCA. Iqirvo is now available for eligible patients in the U.S.
- In April 2023, Merck and Eisai disclosed Phase 3 trial results for advanced melanoma and metastatic colorectal cancer. These trials explore the efficacy of KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib), oral multiple receptor tyrosine kinase inhibitors, respectively
- In March 2023, Bausch Health Companies Inc., a Canadian specialty pharmaceutical company, announced that its Rifaximin SSD (soluble solid dispersion) tablets, combined with lactulose, are in Phase III clinical trials for the treatment of overt hepatic encephalopathy
- In September 2022, GENFIT, a late-stage biopharmaceutical company, announced its acquisition of Versantis, a Swiss-based clinical-stage biotechnology company. Versantis brings a Phase 2-ready program (VS-01-ACLF) based on first-in-class scavenging liposomes technology, a pediatric program for urea cycle disorder (VS-01-UCD), and an early-stage program for hepatic encephalopathy (VS-02-HE)
- In September 2022, GENFIT also revealed that it entered into an exclusivity agreement to acquire all shares and voting rights of Versantis, aimed at addressing unmet medical needs in severe chronic liver diseases
